Toxicity of high dose methotrexate repeated infusions in children treated for acute lymphoblastic leukemia and osteosarcoma;Tossicita da infusioni ripetute di methotrexate ad alte dosi in bambini trattati per leucemia linfoblastica acuta ed osteosarcoma

Minerva Pediatrica

Volumn 48, Issue 5, 1996, Pages 193-200

  Ridolfi, L ^a   Barisone, E ^a   Vivalda, M ^a   Vivenza, C ^a   Brach Del Prever, A ^a   Leone, L ^b   Miniero, R ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Azienda Ospedaliera OIRM   (Italy)

Author keywords

child; lymphocytic acute leukemia; methotrexate adverse effects; osteosarcoma

Indexed keywords

METHOTREXATE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; NEPHROTOXICITY; NEUTROPENIA; OSTEOSARCOMA; THROMBOCYTOPENIA; ACUTE LYMPHOCYTIC LEUKEMIA; BONE TUMOR; DOSE RESPONSE; DRUG EFFECT; KIDNEY; LIVER; PATHOLOGY;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; LEUKEMIA, LYMPHOCYTIC, ACUTE; LIVER; METHOTREXATE; NEUTROPENIA; OSTEOSARCOMA; THROMBOCYTOPENIA;

EID: 0029662073     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Ackland SP, Schilsky RL. High-dose methotrexate a critical reappraisal. J Clin Oncol 1987;5:2017-31.
2. Borsi JD, Sagen E, Romslo I, Moe P. Rescue after intermediate and high-dose methotrexate. background, rationale and current practice. Pediatr Haematol Oncol 1990;7.347-63.
3. Seidel H, Moe PJ, Nygaard R, Nygaard K, Brede W, Borsi JD Evaluation of serious adverse events in patients treated with protocols including methotrexate infusions. Pediatr Haematol Oncol 1994; 11:165-72.
4. 2) in childhood malignancies: clinical tolerabilty and pharmacokinetics. Pediatr Haematol Oncology 1987;4:33-42.
5. Brecher ML, Weinberg Y, Boyett JM et al. Intermediate dose methotrexate in chilhood acute lymphoblastic leukemia resulting in decreased incidence of testicular relapse. Cancer 1986;58:1024-8.
6. Abromowitch M, Ochs J, Pui CH et al. High-dose methotrexate improves clinical outcome in children with acute lyphoblastic leukemia. St. Jude Total Therapy Study X. Med Pediatr Oncol 1988;16.297-303.
7. Borsi JD, Moe PJ. Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children. Cancer 1987;60:3020-4.
8. Evans WE, Crom WR, Stewart CF. Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukemia Lancet 1984;i:359-62
9. Bacci G, Picci P, Ferrari S et al. Primary chemotherapy and delayed surgery for non metastatic osteosarcoma of estremities. Cancer 1993;72:3227-38.
10. Gorin AM, Perez-Atayde A, Gebhardt M et al. Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana Farber Cancer Institute/the Children's Hospital - Study III. J Clin Oncol 1987; 5:1178-84.
11. Rosen G, Marcove RC, Caparros B et al. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 1979; 43:2163-9.
12. Wolfrom C, Hartmann R, Fengler R, Bruhmuller S, Ingwersen I, Henze G. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia J Clin Oncol 1993;11:827-33.
13. Weber BL, Tanyer G, Poplack DG et al Transient acute hepatotoxicity of high-dose methotrexate therapy during chilhood. NCI Monogr 1987;5:207-12.
14. Perez C, Sutow WW, Wang YM, Herson J. Evaluation of overall toxicity of high dosage methotrexate regimens. Med Pediatr Oncol 1979;6:219-28.
15. Locasciulli A, Mura R, Fraschini D et al. High-dose methotrexate administration and acute liver damage in children treated for acute lymphoblastic leukemia. A prospective study. Haematologica 1992, 77:49-53.
16. Relling MV, Fairclough D, Ayers D et al Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994; 12:1667-72.